184
Participants
Start Date
December 9, 2014
Primary Completion Date
June 30, 2016
Study Completion Date
June 30, 2016
Losmapimod tablets
Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
Placebo tablets
Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
Salbutamol MDI
Salbutamol MDI will be provided as a rescue medication.
GSK Investigational Site, Sofia
GSK Investigational Site, Sofia
GSK Investigational Site, Svoge
GSK Investigational Site, San Miguel de Tucumán
GSK Investigational Site, Mendoza
GSK Investigational Site, Dimitrovgrad
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Potsdam
GSK Investigational Site, Hamburg
GSK Investigational Site, Hamburg
GSK Investigational Site, Pozuelo de Alarcón/Madrid
GSK Investigational Site, Hanover
GSK Investigational Site, Valencia
GSK Investigational Site, (Barakaldo) Vizcaya
GSK Investigational Site, Cologne
GSK Investigational Site, Düren
GSK Investigational Site, Koblenz
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Talca
GSK Investigational Site, Santiago
GSK Investigational Site, Santiago
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Mendoza
GSK Investigational Site, São Paulo
GSK Investigational Site, Humenné
GSK Investigational Site, Poprad
GSK Investigational Site, Spišská Nová Ves
GSK Investigational Site, Šaľa
GSK Investigational Site, Vráble
GSK Investigational Site, Incheon
GSK Investigational Site, Seoul
GSK Investigational Site, Alicante
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, L'Hospitalet de Llobregat. Barcelona
Lead Sponsor
GlaxoSmithKline
INDUSTRY